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Title and abstract

Item
No
1

Page number
Recommendation
(a) Indicate the study’s design with a commonly used term in the
title or the abstract

1

(b) Provide in the abstract an informative and balanced summary of
what was done and what was found

3

5-7

Introduction
Background/rationale

2

Explain the scientific background and rationale for the investigation
being reported

Objectives

3

State specific objectives, including any prespecified hypotheses

7

Methods
Study design

4

Present key elements of study design early in the paper

8

Setting

5

Describe the setting, locations, and relevant dates, including periods
of recruitment, exposure, follow-up, and data collection

8

Participants

6

(a) Cohort study—Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources
and methods of case ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources
and methods of selection of participants

17-20
Table 1

(b) Cohort study—For matched studies, give matching criteria and
number of exposed and unexposed
Case-control study—For matched studies, give matching criteria
and the number of controls per case
Variables

7

Clearly define all outcomes, exposures, predictors, potential

16-18

9-11, 32

confounders, and effect modifiers. Give diagnostic criteria, if
applicable
Data sources/
measurement

8*

For each variable of interest, give sources of data and details of
methods of assessment (measurement). Describe comparability of

9-11, 27-29

assessment methods if there is more than one group
Bias

9

Describe any efforts to address potential sources of bias

Study size

10

Explain how the study size was arrived at

Quantitative variables

11

Explain how quantitative variables were handled in the analyses. If
applicable, describe which groupings were chosen and why

Statistical methods

12

(a) Describe all statistical methods, including those used to
control for confounding

27-29

(b) Describe any methods used to examine subgroups and
interactions

28-29

(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up
was addressed
Case-control study—If applicable, explain how matching of cases
and controls was addressed
1

12-13
16
27-29

16
15-16

Cross-sectional study—If applicable, describe analytical methods
taking account of sampling strategy
(e) Describe any sensitivity analyses

Results
Participants

13*

(a) Report numbers of individuals at each stage of study—eg
numbers potentially eligible, examined for eligibility, confirmed
eligible, included in the study, completing follow-up, and
analysed

Figure 2

(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive
data

14*

(a) Give characteristics of study participants (eg demographic,
clinical, social) and information on exposures and potential
confounders

Figure 2
11, 17-19

(b) Indicate number of participants with missing data for each
variable of interest

Outcome data

15*

(c) Cohort study—Summarise follow-up time (eg, average and
total amount)

20-21
Table 1

Cohort study—Report numbers of outcome events or summary
measures over time

9-10

Case-control study—Report numbers in each exposure category,
or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or
summary measures
Main results

16

(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous variables were
categorized
(c) If relevant, consider translating estimates of relative risk into
absolute risk for a meaningful time period

Other analyses

17

Report other analyses done—eg analyses of subgroups and
interactions, and sensitivity analyses

Discussion
Key results

18

Summarise key results with reference to study objectives

Limitations

19

Discuss limitations of the study, taking into account sources of
potential bias or imprecision. Discuss both direction and
magnitude of any potential bias

Interpretation

20

Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence

Generalisability

21

Discuss the generalisability (external validity) of the study
results

Other information
2

Funding

22

Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on which
the present article is based

3

7
Figure 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and
unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is
available at www.strobe-statement.org.
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